[The use of moxonidine in women with arterial hypertension in postmenopausal period].
Bakhshaliev
A B
AB
Sabzalieva
G M
GM
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004394:Dydrogesterone / Q000627:therapeutic use; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D020913:Perindopril / Q000627:therapeutic use; D017698:Postmenopause; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004338:Drug Combinations; D007093:Imidazoles; D008055:Lipids; C472241:femoston; D004958:Estradiol; D004394:Dydrogesterone; C043482:moxonidine; D020913:Perindopril